| Literature DB >> 35535268 |
Helen Endale1, Tefera Mulugeta1, Teshome Habte1.
Abstract
Background: Cervical cancer is very common among women living in low-resource environments, according to the literature. About 85% of the cases and 88% of the deaths due to cervical cancer occurred in developing countries. Women in low- and middle-income countries have a 35% higher average life risk of cervical cancer than women in high-income countries. However, research on the socioeconomic impact of cervical cancer on patients is virtually absent in the country. Objective: To assess the socioeconomic impact of cervical cancer on patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia in 2021.Entities:
Keywords: cervical cancer; economic impact; social impact
Year: 2022 PMID: 35535268 PMCID: PMC9078746 DOI: 10.2147/CMAR.S352389
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.602
Sociodemographic Characteristics of Cervical Cancer Patients at TASH, Addis Ababa, Ethiopia, March 2021 (n=416)
| Variables | Frequency | Percentage |
|---|---|---|
| 30–39 | 79 | 19.0 |
| 40–49 | 150 | 36.1 |
| 50–59 | 100 | 24.0 |
| >60 | 87 | 20.9 |
| Orthodox Christian | 170 | 40.8 |
| Muslim | 133 | 32.0 |
| Protestant | 67 | 16.1 |
| Other | 46 | 11.1 |
| Single | 58 | 13.9 |
| Married | 196 | 47.1 |
| Widowed | 54 | 13.0 |
| Divorced/separated | 108 | 26.0 |
| Cannot read and write | 133 | 32.0 |
| Elementary completed | 108 | 26.0 |
| High school completed | 96 | 23.0 |
| College and above | 79 | 19.0 |
| Urban | 262 | 63.0 |
| Rural | 154 | 37.0 |
Employed
Public Private | ||
| Self-employed | 37 | 8.9 |
| Unemployed | 171 | 41.1 |
| Early stage | 151 | 36.3 |
| Late stage | 265 | 63.7 |
| Not start treatment | 130 | 31 |
| Radiotherapy | 80 | 19 |
| Chemotherapy | 100 | 24 |
| Both radiotherapy and chemotherapy | 61 | 15 |
| All chemotherapy, radiotherapy, brachytherapy | 45 | 11 |
Figure 1Source of financing for medical and nonmedical expenditures of cervical cancer patients at TASH, Addis Ababa, Ethiopia, March 2021.
Results of Multivariable Logistic Regression Analysis for the Outcome Variable “Social Impact Indicators” of Cervical Cancer at TASH, 2021
| Variables | Social Discrimination | AOR (95%CI) | Loss of Sexual Functioning | AOR (95%CI) | Loss of Body Image | AOR (95%CI) | Loss of Femininity | AOR (95%CI) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | Yes | No | |||||
| Urban | 150 | 112 | 1 | 195 | 67 | 1 | 140 | 122 | 1 | 91 | 171 | 1 |
| Rural | 106 | 48 | 1.923 (1.296–3.600)* | 129 | 25 | 0.557 (0.022–2.466) | 122 | 32 | 1.055 (0.062–2.107) | 98 | 56 | 0.771 (0.114–1.955) |
| Employed | 87 | 158 | 1 | 180 | 65 | 1 | 129 | 116 | 1 | 87 | 158 | 1 |
| Unemployed | 169 | 2 | 1.261 (1.021–2.671)** | 144 | 27 | 0.943 (0.277–2.855) | 133 | 38 | 0.654 (0.113–1.996) | 102 | 69 | 0.006 (0.001–1.942) |
| Early stage | 92 | 59 | 1 | 94 | 57 | 1 | 68 | 83 | 1 | 62 | 89 | 1 |
| Late stage | 164 | 101 | 2.809 (1.454–4.332)* | 230 | 35 | 3.443 (1.557–4.069)* | 194 | 71 | 1.812 (1.211–2.444)* | 127 | 138 | 1.452 (1.252–2.500)** |
| Not start treatment | 74 | 56 | 1 | 78 | 52 | 1 | 129 | 101 | 1 | 8 | 122 | 1 |
| Radiotherapy | 52 | 28 | 2.440 (1.457–4.721)** | 70 | 10 | 2.333 (1.943–3.204)* | 63 | 17 | 3.210 (2.001–4.644)* | 54 | 26 | 0.943 (0.243–2.949) |
| Chemotherapy | 59 | 41 | 1.664 (1.212–2.555)* | 89 | 11 | 1.623 (1.213–2.674)* | 81 | 19 | 1.421 (1.251–2.054)* | 62 | 38 | 1.230 (1.001–3.021)** |
| Chemotherapy and radiotherapy | 41 | 20 | 2.011 (1.891–4.005)* | 52 | 9 | 2.000 (1.754–2.910)* | 53 | 8 | 2.572 (1.700–4.000)* | 38 | 23 | 1.632 (1.300–2.696)* |
| Chemotherapy, radiotherapy, and | 30 | 15 | 3.281 (1.743–4.944)** | 35 | 10 | 1.994 (1.219–2.888)* | 36 | 9 | 2.444 (1.496–3.011)** | 27 | 18 | 2.111 (1.621–4.400)* |
Notes: *P-value is significant at 0.05, **-value significant at 0.01.
Results of Multivariable Logistic Regression Analysis for the Outcome Variable “Economic Impact Indicator” of Cervical Cancer at TASH, 2021
| Variables | Loss of Income | AOR (95%CI) | Financial Challenge | AOR (95%CI) | Challenge on Work and Employment | AOR (95%CI) | |||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | ||||
| Urban | 74 | 52 | 1 | 195 | 67 | 1 | 92 | 28 | 1 |
| Rural | 38 | 81 | 1.300 (1.212–2.012)** | 100 | 54 | 2.521 (1.790–3.250)* | 47 | 41 | 0.602 (0.024–0.986)** |
| Early stage | 29 | 102 | 1 | 94 | 57 | 1 | 52 | 45 | 1 |
| Late stage | 83 | 31 | 3.424 (2.001–4.124)* | 201 | 64 | 1.660 (1.222–3.000)* | 87 | 24 | 3.621 (2.001–4.828)** |
| Not start treatment | 12 | 84 | 1 | 44 | 86 | 1 | 14 | 35 | 1 |
| Radiotherapy | 26 | 14 | 2.961 (1.484–3.021)** | 72 | 8 | 1.288 (1.001–3.500)* | 35 | 10 | 1.800 (1.019–2.660)* |
| Chemotherapy | 31 | 12 | 3.011 (1.459–4.550)* | 88 | 12 | 2.100 (1.028–2.888)** | 36 | 11 | 2.117 (1.006–2.442)* |
| Chemotherapy and | 24 | 12 | 1.444 (1.002–2.000)* | 55 | 6 | 1.766 (1.599–3.600)* | 29 | 9 | 3.081 (1.778–3.900)** |
| Chemotherapy, radiotherapy, | 19 | 11 | 2.841 (1.434–3.077)* | 36 | 9 | 1.550 (1.006–2.701)** | 25 | 4 | 2.669 (1.944–3.028)* |
Notes: *P-value is significant at 0.05, **P-value significant at 0.01.